The Global DNA Sequencing Market is Projected to Grow at a CAGR of ~18.02% by 2032 | DelveInsight

The DNA sequencing market is experiencing robust growth fueled by several critical factors, including the rising incidence of genetic disorders and cancer, increasing applications of precision medicine, expanding research in genomics, and ongoing advancements in sequencing technologies that have significantly reduced costs and turnaround times. As a result, the DNA sequencing market is projected to grow steadily between 2025 and 2032.

DelveInsight's DNA sequencing market Insights report provides the current and forecast market analysis, individual leading DNA Sequencing companies' market shares, challenges, DNA sequencing market drivers, barriers, and trends, and key DNA sequencing companies in the market.

Explore the latest trends and growth drivers in the DNA Sequencing Market-download your sample report now https://www.delveinsight.com/report-store/dna-sequencing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the DNA Sequencing Market Report
• The global DNA sequencing market was valued at USD 10.70 billion in 2023 and is projected to grow at a CAGR of 18.02% from 2025 to 2032, reaching approximately USD 28.85 billion by 2032.
• As per DelveInsight estimates, North America is anticipated to dominate the DNA sequencing market during the forecast period.
• Notable DNA sequencing companies such as Agilent Technologies Inc., Biorad Laboratories Ltd, Danaher Corporation, F. Hoffmann-La Roche Ltd, Illumina Inc, PerkinElmer Inc, Merck & Co., Inc, QIAGEN, Thermo Fisher Scientific, PacBio, Macrogen Inc, Oxford Nanopore Technologies plc, CD Genomics, Takara Bio Inc, Promega Corporation, BGI, 10x Genomics, Eurofins Genomics, GENEWIZ (Azenta Life Sciences), and several others are currently operating in the DNA sequencing market.
• In January 2025, Tempus AI launched its FDA-approved xT CDx test nationwide. xT CDx is a 648-gene NGS-based in vitro diagnostic for solid tumor profiling, including microsatellite instability and companion diagnostics for colorectal cancer. Using a normal-matched approach, it improves accuracy in detecting cancer-driving mutations.
• In November 2024, Caris Life Sciences received FDA approval for its MI Cancer Seek assay, a companion diagnostic for multiple targeted therapies across various cancers. It is the first test to combine whole exome and whole transcriptome sequencing, analyzing both DNA and RNA to identify patients most likely to benefit from specific treatments. The test examines 228 genes for mutations, detects microsatellite instability, and measures tumor mutational burden using standard tumor tissue samples.
• In November 2024, HuidaGene Therapeutics, a global clinical-stage biotech company, received FDA clearance to advance HG202, its investigational CRISPR/Cas13 RNA-editing therapy for neovascular age-related macular degeneration (nAMD). Developed using the company's proprietary HG-PRECISE platform, HG202 harnesses AI and machine learning for rapid Cas protein discovery and metagenomic assembly predictions, enabling precise and efficient therapeutic development.
• In May 2022, Limaca Medical, a privately held company located in Israel devoted to enhancing endoscopic biopsy outcomes for patients with potentially life-threatening gastrointestinal tumors, gained FDA breakthrough device classification for its Precision GI endoscopic ultrasound biopsy device. Precision GI is deployed and operated through an instrument channel in the endoscope to biopsy a tumor.

To read more about the latest highlights related to the DNA sequencing market, get a snapshot of the key highlights entailed in the DNA sequencing market report here https://www.delveinsight.com/report-store/dna-sequencing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

DNA Sequencing Overview
DNA sequencing is a powerful molecular biology technique used to determine the precise order of nucleotides within a DNA molecule, enabling comprehensive insights into genetic information. It plays a crucial role in various applications, including clinical diagnostics, personalized medicine, cancer genomics, infectious disease detection, and evolutionary biology. Advances in next-generation sequencing (NGS) have drastically reduced costs and increased throughput, allowing for rapid and large-scale analysis of entire genomes or specific gene panels. This has accelerated research and clinical efforts in identifying disease-causing mutations, tailoring targeted therapies, and advancing precision medicine initiatives.

DNA Sequencing Market Insights
North America is expected to dominate the global DNA sequencing market, primarily driven by a high cancer burden, supportive regulatory policies, and advanced healthcare infrastructure. The rising incidence of cancers, such as breast cancer and other solid tumors, particularly in the United States-as indicated by the American Cancer Society and CDC-continues to boost the demand for next-generation sequencing in diagnostics and personalized medicine. Additionally, strong government initiatives like the $1.7 billion U.S. investment in COVID-19 variant tracking and genome sequencing have enhanced national sequencing capabilities. Coupled with increasing awareness and investments in genomic research and bioinformatics, these factors collectively contribute to the robust growth of the DNA sequencing market in North America.

To know more about why North America is leading the market growth in the DNA sequencing market, get a snapshot of the DNA sequencing market outlook here https://www.delveinsight.com/report-store/dna-sequencing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

DNA Sequencing Market Dynamics
The DNA sequencing market is experiencing significant growth, primarily driven by the rising prevalence of genetic disorders and the increasing adoption of precision medicine. Rare diseases, which affect about 1 in 17 people globally, are often genetic in nature and difficult to diagnose. This has led to growing demand for advanced sequencing technologies like whole genome sequencing, which can identify multiple variant types in a single test and improve diagnostic accuracy. National initiatives, such as the UK's plan to sequence 500,000 genomes, reflect this trend.

Simultaneously, the rise of precision medicine-tailoring cancer treatment based on genetic profiles-is fueling further demand for DNA sequencing. Technologies like next-generation sequencing enable comprehensive tumor analysis, aiding in targeted drug development and individualized therapy plans. However, challenges such as high costs and technical limitations like sequence alignment and read mapping may hinder market expansion.

Get a sneak peek at the DNA sequencing market dynamics @ https://www.delveinsight.com/report-store/dna-sequencing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Coverage: Global
Study Period: 2022 to 2032
DNA Sequencing Market CAGR: ~18.02%
Key DNA Sequencing Companies: Agilent Technologies Inc., Biorad Laboratories Ltd, Danaher Corporation, F. Hoffmann-La Roche Ltd, Illumina Inc, PerkinElmer Inc, Merck & Co., Inc, QIAGEN, Thermo Fisher Scientific, PacBio, Macrogen Inc, Oxford Nanopore Technologies plc, CD Genomics, Takara Bio Inc, Promega Corporation, BGI, 10x Genomics, Eurofins Genomics, GENEWIZ (Azenta Life Sciences), and others.

DNA Sequencing Market Segmentation
Market Segmentation By Products & Services: Instruments, Consumables, and Services.
Market Segmentation By Technology: Sanger Sequencing, Next-Generation Sequencing, and Long-Read Sequencing.
Market Segmentation By Application: Disease Diagnosis, Precision Medicine, and Research
Market Segmentation By End User: Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical Companies, and Academic Institutes.
Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World

Which MedTech key players in the DNA sequencing market are set to emerge as the trendsetter, explore @ https://www.delveinsight.com/report-store/dna-sequencing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. DNA Sequencing Market Report Introduction
2. DNA Sequencing Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. DNA Sequencing Market Key Factors Analysis
6. DNA Sequencing Market Porter's Five Forces Analysis
7. DNA Sequencing Market Layout
8. DNA Sequencing Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.